KR920003970A - 혈중 요산 함량의 강하 방법 - Google Patents

혈중 요산 함량의 강하 방법 Download PDF

Info

Publication number
KR920003970A
KR920003970A KR1019910013330A KR910013330A KR920003970A KR 920003970 A KR920003970 A KR 920003970A KR 1019910013330 A KR1019910013330 A KR 1019910013330A KR 910013330 A KR910013330 A KR 910013330A KR 920003970 A KR920003970 A KR 920003970A
Authority
KR
South Korea
Prior art keywords
acid content
uric acid
blood uric
lower blood
mammal
Prior art date
Application number
KR1019910013330A
Other languages
English (en)
Other versions
KR940002665B1 (ko
Inventor
씨. 고잉 파든
Original Assignee
알렌 제이. 스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렌 제이. 스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이. 스피겔
Publication of KR920003970A publication Critical patent/KR920003970A/ko
Application granted granted Critical
Publication of KR940002665B1 publication Critical patent/KR940002665B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

내용 없음

Description

혈중 요산 함량의 강하 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 하기 일반식(I)의 화합물 또는 그의 약학적으로 허용되는 염기 부가염(이때, R1은 하이드록시이다)을 포유동물에게 투여함을 특징으로 하는 포유동물의 혈중 요산 함량을 강하시키는 방법.
    상기식에서, R1은 하이드록시 또는 전구약물 그룹이고, R2및 R3는 독립적으로 수소, 플루오로, 클로로 또는 트리플루오로메틸이나, 단, R2및 R3둘다는 수소가 아니다.
  2. 제1항에서 R2가 수소이고, R3가 트리플루오로메틸인 방법.
  3. 제1항에 정의된 바와 같은 일반식(I)의 화합물과 약학적으로 허용되는 담체를 포함함을 특징으로 하는, 포유동물의 혈중 요산함량을 강하시키기 위한 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910013330A 1990-08-02 1991-08-01 혈중 요산 함량 강하조성물 KR940002665B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/562,096 1990-08-02
US562,096 1990-08-02
US07/562,096 US5064830A (en) 1990-08-02 1990-08-02 Lowering of blood uric acid levels

Publications (2)

Publication Number Publication Date
KR920003970A true KR920003970A (ko) 1992-03-27
KR940002665B1 KR940002665B1 (ko) 1994-03-28

Family

ID=24244779

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910013330A KR940002665B1 (ko) 1990-08-02 1991-08-01 혈중 요산 함량 강하조성물

Country Status (16)

Country Link
US (1) US5064830A (ko)
EP (1) EP0469837B1 (ko)
JP (1) JPH04234321A (ko)
KR (1) KR940002665B1 (ko)
AT (1) ATE113840T1 (ko)
AU (1) AU622590B2 (ko)
CA (1) CA2048235C (ko)
DE (1) DE69105069T2 (ko)
DK (1) DK0469837T3 (ko)
HU (1) HUT61665A (ko)
IE (1) IE64046B1 (ko)
IL (1) IL98979A (ko)
MX (1) MX9100450A (ko)
NZ (1) NZ239215A (ko)
PT (1) PT98509B (ko)
ZA (1) ZA916060B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
IL120264A0 (en) * 1996-02-29 1997-06-10 Pfizer Method of reducing tissue damage associated with non-cardiac ischemia
IL124236A (en) * 1997-05-05 2003-01-12 Pfizer Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor
WO2011046800A1 (en) * 2009-10-13 2011-04-21 Wellstat Therapeutics Corporation 3-substituted compounds for reducing uric acid
WO2017176777A1 (en) * 2016-04-04 2017-10-12 Aviragen Therapeutics, Inc. Bta-c585 for the treatment and/or prevention of conditions related to or associated with hyperuricemia or hyperuricosuria and other conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
ES2032749T3 (es) * 1985-11-07 1993-03-01 Pfizer Inc. Acidos oxoftalazinil-aceticos heterociclicos.
GB8704569D0 (en) * 1987-02-26 1987-04-01 Ici America Inc Therapeutic agent
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
EP0322153A3 (en) * 1987-12-21 1990-08-16 Pfizer Inc. Heterocyclic oxophtalazinyl acetic acids

Also Published As

Publication number Publication date
IE64046B1 (en) 1995-06-28
IL98979A (en) 1996-11-14
HUT61665A (en) 1993-03-01
ATE113840T1 (de) 1994-11-15
CA2048235C (en) 1995-05-30
DE69105069D1 (de) 1994-12-15
PT98509A (pt) 1992-06-30
ZA916060B (en) 1993-03-31
AU8156091A (en) 1992-02-06
IE912721A1 (en) 1992-02-12
EP0469837B1 (en) 1994-11-09
DK0469837T3 (da) 1994-12-27
EP0469837A2 (en) 1992-02-05
PT98509B (pt) 1999-01-29
KR940002665B1 (ko) 1994-03-28
AU622590B2 (en) 1992-04-09
HU912567D0 (en) 1992-01-28
EP0469837A3 (en) 1992-04-08
US5064830A (en) 1991-11-12
NZ239215A (en) 1997-07-27
MX9100450A (es) 1992-04-01
JPH04234321A (ja) 1992-08-24
DE69105069T2 (de) 1995-03-09
IL98979A0 (en) 1992-07-15

Similar Documents

Publication Publication Date Title
KR920012040A (ko) 신규의 디히드로-이소퀴놀린 유도체
KR840004106A (ko) 4급 6,11-디하이드로-디벤조-[b,e]-티에핀-11-N-알킬-노르스코핀 에테르의 제조방법
ATE153022T1 (de) 3',5'-ditertbutyl-4'-hydroxyflavone, verfahren zu ihrer herstellung und pharmazeutische zusammensetzung mit antioxidations- und antivasokonstriktionsaktivität
DE59208974D1 (de) Neue pyrazinderivative, ihre herstellung und verwendung
KR860700250A (ko) 신규 아미딘 화합물
KR920003970A (ko) 혈중 요산 함량의 강하 방법
DE3869075D1 (de) 2-piperazinyl-2-oxo-aethylensubstituierte flavonoid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammenstellungen.
KR890006639A (ko) 벤조티아진 디옥사이드 유도체
KR880010766A (ko) 인터루킨-1의 방출을 억제하고 인터루킨-1이 개재된 질환을 완화시키는 방법
KR920004387A (ko) 진통제 및 피부질환 치료용 국소용 소염제로서의 4-치환된 디하이드로피리도[4,3-d]피리미딘
KR910014380A (ko) 이미자조피리다진 화합물, 그의 제법 및 용도
KR830004292A (ko) 벤조구아나민 유도체의 제조방법
KR840004422A (ko) 사이프로헵타딘-3-카복실산의 에스테르 및 관련 화합물의 제조방법
KR870003994A (ko) 도파민-β-하이드록시라제 억제제
KR830004320A (ko) 퀴나졸린 유도체의 제조방법
KR880009944A (ko) 피페라진 카르복실산, 그의 제조방법 및 그를 함유하는 약학적 조성물
KR850003382A (ko) 디아릴인단-1,3-디온의 제조방법
KR920005720A (ko) 피리딘 유도체 그 제조방법 및 그 약학적 조성물
KR920002594A (ko) 5-이소티아졸아민 유도체
KR850003407A (ko) 유기인산 에스테르 유도체의 제조방법
KR900701273A (ko) 진토성 에르골린 유도체
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법
DE59304476D1 (de) Lagerstabile Lösungen von carbonisiertem Magnesiumethylat in Ethanol sowie deren Herstellung und Verwendung
KR910011258A (ko) 녹내장의 치료방법
KR840001144A (ko) 5(6)-페닐설포닐옥시-벤즈이미다졸 유도체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20000229

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee